Clinical Scorecard: Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents

At a Glance

Key Highlights

• HCC is a leading cause of cancer-related mortality globally.
• Chronic HCV infection is a significant risk factor for HCC development.
• Telomere length may serve as a prognostic biomarker for HCC.
• DAA treatments achieve high viral clearance rates but may have long-term implications for HCC risk.
• Telomerase reactivation is observed in over 90% of HCC cases.

Guideline-Based Recommendations

Diagnosis

• HCC diagnosis confirmed via histopathological examination.

Management

• Utilization of direct-acting antiviral agents (DAA) for chronic HCV treatment.

Monitoring & Follow-up

• Long-term monitoring of telomere length and HCC incidence post-DAA therapy.

Risks

• Potential increased incidence of HCC following DAA therapy.

Patient & Prescribing Data

Patients with chronic HCV infection and cirrhosis.

DAA regimens achieve sustained virologic response exceeding 90%.

Clinical Best Practices

• Assess telomere length as a potential biomarker in HCC patients.
• Monitor liver disease progression in patients post-DAA treatment.
• Conduct comprehensive investigations into long-term molecular consequences of antiviral treatments.

References

• Source Article